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Poor Pulmonary Function is Not Associated with 
Increased Rates of Toxicity or Decreased Overall 
Survival After Stereotactic Body Radiotherapy 
for Early Stage Non-Small Cell Lung Cancer: 
Results of a Multi-institutional Analysis
Purpose/Objective(s)
Stereotactic body radiotherapy (SBRT) is considered as the treatment 
of choice for stage I non-small cell lung cancer (NSCLC) in medically 
inoperable patients. It was the purpose of this study to evaluate 
whether pretreatment pulmonary function is predictive for survival 
and toxicity after SBRT.
Materials/Methods
Between 1998 and 2009, 411 patients were treated with SBRT for 434 
targets of cT1 -cT3 cN0 NSCLC at five international radiotherapy 
departments. Median age of the patients was 74 years ranging 
between 42 and 92. Median tumor diameter was 2.4cm with a 
maximum tumor size of 8.5cm. Patients were treated with various 
fractionation schemas of median 3 treatment fractions (range 1 to 15) 
and a median total dose of 54Gy (20Gy to 64Gy). All treatments had 
in common that daily volumetric image guidance for verification of 
the target position and online correction of set-up errors and baseline 
shifts was performed for all patients.
Results
Data of pre-treatment pulmonary function tests (PFT) were available 
for 83% (FEV1 absolute and predicted), 65% (DLCO predicted) and 
37% (DLCO actual) of the patients and median interval between PFT 
and start of SBRT was 35 days. Median pretreatment actual FEV1 
was 1.4l (0.43l to 4.4l) and predicted FEV1 was 65% (21% to 286%). 
Median actual DLCO was 11.7 CO/mmHg/min (3.4 CO/mmHg/min 
to 24.2 CO/mmHg/min) and median predicted DLCO was 53% (10% 
to 103%). Pretreatment pulmonary function was significantly different 
between the five institutions: median FEV1 was 1.6l and 1.2l in the 
institutions with best and worst pulmonary function. Median follow-up 
was 12 months; follow-up was longer than 2 years in 23% of the patients. 
Two-year overall survival (OS) was 64% for all patients and pneumonitis 
grade >=II was observed in 6%. Using log-rank test, actual and predicted 
DLCO as well as actual FEV1 were significantly correlated with OS. Two-
year OS was 47% and 74% for patients with DLCO maximum 9.7 CO/
mmHg/min and more than 9.7 CO/mmHg/min, respectively (p=0.002); 
two-years OS was 44% and 64% for patients with FEV1 maximum 0.95l 
and more than 0.95l, respectively (p=0.01). In the multivariate analysis, 
this correlation between PFT overall survival did not remain statistically 
significant. No correlation between pretreatment PFT and pneumonitis 
grade >=II was observed.
Conclusion
Pretreatment pulmonary function was significantly different 
between the five institutions. Poor pulmonary function did not result 
in increased rates of toxicity or decreased overall survival after image 
guided SBRT. Poor pulmonary function within the range reported in 
this study should therefore not be a contraindication for SBRT.
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